

# Jia-Nan Gong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5532176/publications.pdf>

Version: 2024-02-01

10  
papers

1,721  
citations

933447

10  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

3203  
citing authors

#	ARTICLE	IF	CITATIONS
1	The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. <i>Leukemia</i> , 2021, 35, 2114-2118.	7.2	18
2	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2217-2233.	11.2	29
3	BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines. <i>Blood Advances</i> , 2020, 4, 356-366.	5.2	16
4	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nature Communications</i> , 2019, 10, 2385.	12.8	139
5	KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. <i>Journal of Controlled Release</i> , 2019, 296, 40-53.	9.9	39
6	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discovery</i> , 2018, 8, 1582-1597.	9.4	310
7	IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. <i>Blood</i> , 2018, 132, 2166-2178.	1.4	65
8	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	148
9	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. <i>Blood</i> , 2016, 128, 1834-1844.	1.4	127
10	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature</i> , 2016, 538, 477-482.	27.8	830